Circulation最新文献

筛选
英文 中文
Technology and Intelligence: Staying on Target for the Next Decade of Electrophysiology. 技术与智能:电生理学下一个十年的目标。
IF 41.3 1区 医学
Circulation Pub Date : 2026-11-10 Epub Date: 2026-11-09 DOI: 10.1161/CIRCULATIONAHA.126.080523
Roderick Tung
{"title":"Technology and Intelligence: Staying on Target for the Next Decade of Electrophysiology.","authors":"Roderick Tung","doi":"10.1161/CIRCULATIONAHA.126.080523","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.080523","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"154 19","pages":"1881-1883"},"PeriodicalIF":41.3,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reconsidering β-Blockers in HFpEF: An Urgent Priority. 重新考虑β-阻滞剂在HFpEF中的应用:当务之急。
IF 41.3 1区 医学
Circulation Pub Date : 2026-11-10 Epub Date: 2026-11-09 DOI: 10.1161/CIRCULATIONAHA.126.083111
Parag Goyal, Andrew P Ambrosy, Markus Meyer
{"title":"Reconsidering β-Blockers in HFpEF: An Urgent Priority.","authors":"Parag Goyal, Andrew P Ambrosy, Markus Meyer","doi":"10.1161/CIRCULATIONAHA.126.083111","DOIUrl":"10.1161/CIRCULATIONAHA.126.083111","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"154 19","pages":"1877-1880"},"PeriodicalIF":41.3,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter by Fan et al Regarding Article, "Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-Analysis of 71 683 Participants Randomized to NOAC Versus Warfarin". Fan等人关于文章“房颤的系统性栓塞事件:71683名随机分到NOAC组和华法林组的个体患者数据荟萃分析”的信。
IF 41.3 1区 医学
Circulation Pub Date : 2026-11-10 Epub Date: 2026-11-09 DOI: 10.1161/CIRCULATIONAHA.126.080832
Yongqiang Fan, Shunxuan Yan, Xiwen Simon Qin
{"title":"Letter by Fan et al Regarding Article, \"Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-Analysis of 71 683 Participants Randomized to NOAC Versus Warfarin\".","authors":"Yongqiang Fan, Shunxuan Yan, Xiwen Simon Qin","doi":"10.1161/CIRCULATIONAHA.126.080832","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.080832","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"154 19","pages":"e683-e684"},"PeriodicalIF":41.3,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CCND1 Mitigates Ischemia-Induced Pathological Cardiac Remodeling by Promoting Cardiac Monocyte-Derived Macrophage Transition to a Reparative Phenotype. CCND1通过促进心脏单核细胞来源的巨噬细胞向修复表型过渡来减轻缺血诱导的病理性心脏重塑。
IF 41.3 1区 医学
Circulation Pub Date : 2026-11-10 Epub Date: 2026-09-15 DOI: 10.1161/CIRCULATIONAHA.126.079966
Chuhan Wang, Huian Han, Kailai Li, Lai Zhang, Chuanjun Shu, Liyuan Cao, Mengxuan Zhang, Yating Yang, Shenghang Liu, Hao Shi, Chen Liu, Hui Bai, Jingjing Ben, Xudong Zhu, Xiaoyu Li, Qing Yang, Dongdong Wang, Feng Chen, Yigang Zhong, Hao Wang, Lian-Sheng Wang, Hanwen Zhang, Qi Chen
{"title":"CCND1 Mitigates Ischemia-Induced Pathological Cardiac Remodeling by Promoting Cardiac Monocyte-Derived Macrophage Transition to a Reparative Phenotype.","authors":"Chuhan Wang, Huian Han, Kailai Li, Lai Zhang, Chuanjun Shu, Liyuan Cao, Mengxuan Zhang, Yating Yang, Shenghang Liu, Hao Shi, Chen Liu, Hui Bai, Jingjing Ben, Xudong Zhu, Xiaoyu Li, Qing Yang, Dongdong Wang, Feng Chen, Yigang Zhong, Hao Wang, Lian-Sheng Wang, Hanwen Zhang, Qi Chen","doi":"10.1161/CIRCULATIONAHA.126.079966","DOIUrl":"10.1161/CIRCULATIONAHA.126.079966","url":null,"abstract":"<p><strong>Background: </strong>The innate immune system plays a pivotal role in orchestrating the response to myocardial infarction (MI), with monocytes and macrophages acting as central mediators of tissue injury and repair. Following MI, a dynamic sequence of inflammatory, anti-inflammatory, and reparative phases unfolds over the course of several days. While timely resolution of inflammation and initiation of reparative programs are critical for favorable cardiac remodeling and improved long-term outcomes, the mechanisms by which recruited monocyte-derived macrophages are instructed within the postinfarct niche to adopt a reparative phenotype remain incompletely understood.</p><p><strong>Methods: </strong>Human peripheral blood mononuclear cells were isolated from individuals with and without MI for single-cell RNA sequencing analysis. The murine cardiac monocyte-derived macrophage behaviors after MI were characterized by genetic lineage tracing, lineage tracing plus bone marrow transplantation, metabolite profiling, and cell phenotyping approaches. The role of macrophage CCND1 (cyclin D1) in MI-induced adverse remodeling was investigated using macrophage-specific <i>Ccnd1</i> knockout mice. Epigenetic experiments were conducted to study the mechanisms underlying metabolic reprogramming and macrophage phenotypic transition. The therapeutic efficacy of lentivirus-targeting macrophage CCND1 and its downstream regulator PDK4 (pyruvate dehydrogenase kinase 4) were assessed in vivo using an MI mouse model.</p><p><strong>Results: </strong>We found that CCND1 levels in peripheral blood mononuclear cells, monocytes, and cardiac macrophages from patients with MI were significantly decreased. Both macrophage-specific and monocyte-derived macrophage-specific deletion of CCND1 worsened MI-induced cardiac dysfunction and adverse remodeling, driven by amplified inflammatory responses. Mechanistically, CCND1 directly interacted with PDK4 and facilitated its ubiquitination by recruiting RPL11 (ribosomal protein L11) and mouse double minute 2. Through this axis, CCND1 suppressed PDK4-driven PDH (pyruvate dehydrogenase) phosphorylation, enhanced glucose oxidation, and shifted macrophages toward an anti-inflammatory phenotype. Targeted overexpression of the CCND1-PDK4 binding motif or knockdown of PDK4 in macrophages improved cardiac function and mitigated adverse remodeling after MI, independent of the canonical cell cycle-regulatory role of CCND1.</p><p><strong>Conclusions: </strong>Our findings identify the CCND1-PDK4 axis as a key regulator of macrophage functional reprogramming toward a reparative phenotype after MI, highlighting it as a potential therapeutic target in postinfarction remodeling.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"1904-1924"},"PeriodicalIF":41.3,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148966912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Association Between Hospital Comprehensive Stroke Center Designation Status and Stroke Rate Reporting in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry After Transcatheter Aortic Valve Replacement: Implications for Hospital Performance Assessment. 在胸外科学会/美国心脏病学会经导管主动脉瓣置换术后经导管瓣膜治疗登记中,医院综合卒中中心指定状态与卒中发生率报告之间的关系:对医院绩效评估的影响
IF 41.3 1区 医学
Circulation Pub Date : 2026-11-10 Epub Date: 2026-09-29 DOI: 10.1161/CIRCULATIONAHA.125.078584
G Michael Deeb, P Michael Grossman, Pratik Manandbar, Joseph E Bavaria, John Carroll, Mohamad A Alkhouli, Joseph C Cleveland, Kim Guibone, Deana Harbach, Tsuyoshi Kaneko, Neil S Kleiman, Dharam J Kumbhani, Joan Michaels, Wayne Batchelor, Vinod H Thourani, Sreekanth Vemulapalli
{"title":"The Association Between Hospital Comprehensive Stroke Center Designation Status and Stroke Rate Reporting in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry After Transcatheter Aortic Valve Replacement: Implications for Hospital Performance Assessment.","authors":"G Michael Deeb, P Michael Grossman, Pratik Manandbar, Joseph E Bavaria, John Carroll, Mohamad A Alkhouli, Joseph C Cleveland, Kim Guibone, Deana Harbach, Tsuyoshi Kaneko, Neil S Kleiman, Dharam J Kumbhani, Joan Michaels, Wayne Batchelor, Vinod H Thourani, Sreekanth Vemulapalli","doi":"10.1161/CIRCULATIONAHA.125.078584","DOIUrl":"10.1161/CIRCULATIONAHA.125.078584","url":null,"abstract":"<p><strong>Background: </strong>The Michigan Structural Heart Consortium showed that transcatheter aortic valve replacement (TAVR) stroke rates were associated with hospital Comprehensive Stroke Center (CSC) designation, suggesting that hospital structural factors affect stroke reporting. We sought to determine whether CSC designation is nationally associated with reported stroke rates and the potential impact on hospital performance and Transcatheter Valve Therapy National Data Registry (TVTR) public reporting.</p><p><strong>Methods: </strong>Consecutive TVTR cases from January 2016 through June 2023 were included, excluding sites reporting to the TVTR <1 year or performing <20 total TAVR procedures. The primary outcome was in-hospital stroke rate. Secondary outcomes were disabling stroke and 30-day stroke. Major bleeding, death, acute renal failure, and a composite end point were falsification end points to determine whether CSC status was uniquely associated with stroke. Multivariable hierarchical models were created starting with patient covariates and sequentially adding hospital variables to account for determinants of stroke. The impact of CSC status on hospital performance was estimated by correcting CSC hospital stroke rates in the validated TVTR 30-day composite model.</p><p><strong>Results: </strong>A total of 525 919 TAVRs at 800 sites were included, and 10 963 strokes (2.1%) were reported within 30 days: 8284 (1.6%) in-hospital and 2679 (0.5%) after discharge. A total of 4733 (0.9%) were disabling strokes. Multivariate analysis showed that CSC status and participation in TAVR trials were independent predictors of in-hospital stroke rate (<i>P</i>=0.033 and 0.012) and disabling stroke (<i>P</i>=0.033 and 0.007), but not falsification end points (<i>P</i>=NS). Participation in TAVR trials and operator volume were independent predictors of 30-day stroke (<i>P</i>=0.039 and <i>P</i>=0.041). The impact of CSC status on the 30-day composite model showed performance improvement for 8 of 153 CSC hospitals.</p><p><strong>Conclusions: </strong>CSC hospital status and participation in TAVR trials are significant predictors unique for stroke. Correcting for the association of CSC status on stroke rate resulted in an estimated 8 of 153 hospitals improving their TVTR 30-day composite model performance. Further work is needed to account for potential ascertainment bias for stroke in public reporting.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"1939-1949"},"PeriodicalIF":41.3,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progressive Calcification and Stenosis of a Quadricuspid Aortic Valve. 四尖瓣进行性钙化和狭窄。
IF 41.3 1区 医学
Circulation Pub Date : 2026-11-10 Epub Date: 2026-11-09 DOI: 10.1161/CIRCULATIONAHA.126.082295
Daisuke Fukamachi, Naoya Matsumoto, Yasuo Okumura
{"title":"Progressive Calcification and Stenosis of a Quadricuspid Aortic Valve.","authors":"Daisuke Fukamachi, Naoya Matsumoto, Yasuo Okumura","doi":"10.1161/CIRCULATIONAHA.126.082295","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.082295","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"154 19","pages":"1973"},"PeriodicalIF":41.3,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Myocardial Responses to Eplontersen in Transthyretin Amyloid Cardiomyopathy: The CARDIO-TTRansform CMR study. 转甲状腺素淀粉样心肌病患者对Eplontersen的心肌反应:CARDIO-TTRansform CMR研究。
IF 41.3 1区 医学
Circulation Pub Date : 2026-11-09 DOI: 10.1161/CIRCULATIONAHA.126.083732
Yousuf Razvi, Scott D Solomon, Sarah A M Cuddy, Lucia Venneri, Ana Martinez-Naharro, Francesco Cappelli, Alberto Cipriani, Pablo Garcia-Pavia, Ahmad Masri, Awais Sheikh, Noemi Ramos-Lopez, Priya Sekar, Tom Conrad, Brian Claggett, Peter Kellman, Farooq H Sheikh, Justin L Grodin, Charlotte Manisty, George D Thornton, James C Moon, Mathew S Maurer, Franca S Angeli, Jersey Chen, Sotirios Tsimikas, Julian D Gillmore, Marianna Fontana
{"title":"Myocardial Responses to Eplontersen in Transthyretin Amyloid Cardiomyopathy: The CARDIO-TTRansform CMR study.","authors":"Yousuf Razvi, Scott D Solomon, Sarah A M Cuddy, Lucia Venneri, Ana Martinez-Naharro, Francesco Cappelli, Alberto Cipriani, Pablo Garcia-Pavia, Ahmad Masri, Awais Sheikh, Noemi Ramos-Lopez, Priya Sekar, Tom Conrad, Brian Claggett, Peter Kellman, Farooq H Sheikh, Justin L Grodin, Charlotte Manisty, George D Thornton, James C Moon, Mathew S Maurer, Franca S Angeli, Jersey Chen, Sotirios Tsimikas, Julian D Gillmore, Marianna Fontana","doi":"10.1161/CIRCULATIONAHA.126.083732","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.083732","url":null,"abstract":"<p><strong>Background: </strong>Transthyretin-lowering therapies target the underlying cause of transthyretin amyloid cardiomyopathy (ATTR-CM), but their effects on myocardial amyloid burden and cardiac remodelling remain incompletely characterized. We evaluated the myocardial effects of sustained transthyretin suppression with eplontersen using serial multiparametric cardiovascular magnetic resonance (CMR).</p><p><strong>Methods: </strong>This CMR study was a pre-specified, international, prospective study embedded within the randomized, placebo-controlled phase 3 CARDIO-TTRansform trial. Participants underwent CMR at baseline and planned assessments at weeks 25, 49, 97, and 140. The primary imaging analysis evaluated longitudinal changes in CMR parameters using mixed models for repeated measures. Myocardial amyloid regression and progression were defined as ≥5 percentage-point decreases and increases in extracellular volume (ECV), respectively. All other patients were considered stable.</p><p><strong>Results: </strong>We enrolled 120 participants with baseline and ≥1 follow-up CMR assessment (eplontersen, n=58; placebo, n=62; mean age, 76.7±6.5 years; 95% male; baseline stabilizer, 12.5%). At week 140 eplontersen resulted in lower ECV, compared with placebo (least-squares mean difference [95% CI], -6.7 percentage points [ -8.7 to -4.7]; P<0.001) and lower native T1 ( -25.9ms [-41.7 to -10.2 ]; P=0.002) and left ventricular mass (-19.1g [-28.0 to -10.2]; P<0.001). Eplontersen also increased left ventricular ejection fraction (+5.1% [1.8-8.3]; P=0.002), right ventricular ejection fraction (+4.6% [0.6-8.7]; P=0.03), and left ventricular global longitudinal, circumferential, and radial strain and right ventricular longitudinal strain (all P<0.05), compared to placebo. At week-140, myocardial amyloid regression occurred in 12.5% receiving eplontersen versus 0% receiving placebo, whereas progression occurred in 12.5% versus 76%, respectively.</p><p><strong>Conclusions: </strong>Sustained transthyretin suppression with eplontersen resulted in substantially lower myocardial ECV and favorable changes in cardiac structure, biventricular systolic function, and myocardial deformation compared with placebo in a cohort of patients mostly not on background stabilizer at baseline. These findings provide randomized evidence that lowering circulating transthyretin modifies myocardial disease progression in ATTR-CM and support serial multiparametric CMR for characterizing myocardial treatment response.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of Eplontersen on Cardiac Structure and Function in Patients With Transthyretin Amyloidosis With Cardiomyopathy: Insights from the CARDIO-TTRansform Trial. Eplontersen对转甲状腺蛋白淀粉样变合并心肌病患者心脏结构和功能的影响:来自CARDIO-TTRansform试验的见解
IF 41.3 1区 医学
Circulation Pub Date : 2026-11-09 DOI: 10.1161/CIRCULATIONAHA.126.083722
Karola S Jering, Hicham Skali, Brian Claggett, Narayana Prasad, Jersey Chen, Esther Gonzalez-Lopez, Caroline Morbach, Sarah A M Cuddy, Margot K Davis, Fabio Fernandes, Joshua D Mitchell, Nitasha Sarswat, Marcus A Urey, Elke Platz, Sotirios Tsimikas, Mathew S Maurer, Marianna Fontana, Scott D Solomon
{"title":"Effects of Eplontersen on Cardiac Structure and Function in Patients With Transthyretin Amyloidosis With Cardiomyopathy: Insights from the CARDIO-TTRansform Trial.","authors":"Karola S Jering, Hicham Skali, Brian Claggett, Narayana Prasad, Jersey Chen, Esther Gonzalez-Lopez, Caroline Morbach, Sarah A M Cuddy, Margot K Davis, Fabio Fernandes, Joshua D Mitchell, Nitasha Sarswat, Marcus A Urey, Elke Platz, Sotirios Tsimikas, Mathew S Maurer, Marianna Fontana, Scott D Solomon","doi":"10.1161/CIRCULATIONAHA.126.083722","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.083722","url":null,"abstract":"<p><strong>Background: </strong>In CARDIO-TTRansform, the TTR (transthyretin) silencer eplontersen did not significantly reduce the primary end point of cardiovascular death and recurrent cardiovascular events in patients with TTR amyloidosis with cardiomyopathy, although treatment effects varied by baseline TTR stabilizer use. Whether eplontersen favorably affects cardiac structure and function is unknown.</p><p><strong>Methods: </strong>CARDIO-TTRansform randomized 1432 patients with TTR amyloidosis with cardiomyopathy to eplontersen (45 mg) subcutaneously every 4 weeks or placebo. Echocardiograms were performed at baseline and weeks 61, 97, and 140. Associations of baseline echocardiographic measures with all-cause mortality and the primary end point were evaluated using Cox and semiparametric proportional rates models. Between-group differences at week 140 were analyzed with mixed models for repeated measures.</p><p><strong>Results: </strong>Among 1426 participants with baseline echocardiograms (mean age, 76±7 years, 91% men, 85% wild type, 57% receiving stabilizers), baseline measures of left ventricular systolic function (LV ejection fraction, global longitudinal strain, stroke volume, myocardial contraction fraction), diastolic function (E wave deceleration time, septal e', average E/e'), and right ventricular function and hemodynamics were independently associated with all-cause mortality or the primary end point. At week 140 (echocardiograms available in 554 patients in the eplontersen group and 506 in the placebo group), eplontersen attenuated increases in mean LV wall thickness (least-squares mean [LSM] difference, -0.24 mm [95% CI, -0.48 to -0.01]) and declines in LV stroke volume (LSM difference, 1.88 mL [95% CI, 0.07-3.69]), myocardial contraction fraction (LSM difference, 0.88% [95% CI, 0.25-1.57]), average E/e' (LSM difference, -0.71 [95% CI, -1.36 to -0.07]), and right ventricular outflow tract velocity-time integral (LSM difference, 0.42 [95% CI, 0.00-0.85]) versus placebo in the overall cohort. Beneficial effects were driven almost exclusively by patients not receiving stabilizers at baseline. No significant treatment effects were observed in patients receiving stabilizers.</p><p><strong>Conclusions: </strong>Among patients with TTR amyloidosis with cardiomyopathy, eplontersen modestly attenuated deterioration in prognostically important measures of LV systolic, diastolic and right ventricular function, primarily among patients not receiving stabilizers at baseline. These findings complement the clinical findings of CARDIO-TTRansform and suggest that TTR silencing may attenuate progression of cardiac dysfunction in TTR amyloidosis with cardiomyopathy.</p><p><strong>Registration: </strong>URL: https://www.clinicaltrials.gov; Unique identifier: NCT04136171; URL: xxx; Unique identifier: 2019-002835-27.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Leveraging Multimodality Imaging to Inform Therapeutic Mechanism, Treatment Response, and Patient Discussions in ATTR-CM. 利用多模态成像告知atr - cm的治疗机制、治疗反应和患者讨论。
IF 41.3 1区 医学
Circulation Pub Date : 2026-11-09 DOI: 10.1161/CIRCULATIONAHA.126.084113
Senthil Selvaraj, Paco Bravo
{"title":"Leveraging Multimodality Imaging to Inform Therapeutic Mechanism, Treatment Response, and Patient Discussions in ATTR-CM.","authors":"Senthil Selvaraj, Paco Bravo","doi":"10.1161/CIRCULATIONAHA.126.084113","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.084113","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of Sotatercept on Cardiac Structure and Function in Combined Post- and Precapillary Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: Analysis of the CADENCE Study. 索特西普对保留射血分数的心力衰竭合并毛细血管后和前肺动脉高压患者心脏结构和功能的影响:CADENCE研究的分析。
IF 41.3 1区 医学
Circulation Pub Date : 2026-11-08 DOI: 10.1161/CIRCULATIONAHA.126.083993
Ryan J Tedford, Roberto Badagliacca, Rabea Asleh, Alessia Urbinati, Grzegorz Kopeć, David Langleben, Stephan Rosenkranz, Ronen Rubinshtein, Daniel N Silverman, Roham Zamanian, Ronald Zolty, Barry Miller, Aaron D Jones, Yaru Shi, Chih-Chin Liu, Ciaran J McMullan, Jean-Luc Vachiery, Mardi Gomberg-Maitland
{"title":"Effects of Sotatercept on Cardiac Structure and Function in Combined Post- and Precapillary Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: Analysis of the CADENCE Study.","authors":"Ryan J Tedford, Roberto Badagliacca, Rabea Asleh, Alessia Urbinati, Grzegorz Kopeć, David Langleben, Stephan Rosenkranz, Ronen Rubinshtein, Daniel N Silverman, Roham Zamanian, Ronald Zolty, Barry Miller, Aaron D Jones, Yaru Shi, Chih-Chin Liu, Ciaran J McMullan, Jean-Luc Vachiery, Mardi Gomberg-Maitland","doi":"10.1161/CIRCULATIONAHA.126.083993","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.083993","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书